08:00 , Mar 2, 2015 |  BioCentury  |  Strategy

Sosei finds its R&D engine

Sosei Group Corp. has only one clinical candidate in development, but the Japanese biotech may have found its R&D engine in drug discovery platform company Heptares Therapeutics Ltd. The M&A deal marks a clean break...
07:00 , Jun 28, 2010 |  BioCentury  |  Strategy

Sosei's Consolidation Play

Japanese biotech and pharma companies, including Sosei Group Corp. , have tended to build their businesses by acquiring foreign assets. Sosei's acquisition of Activus Pharma Co. Ltd. , a Japanese nanoparticle-based formulation company, breaks the...
07:00 , May 31, 2010 |  BioCentury  |  Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
07:00 , May 19, 2008 |  BC Week In Review  |  Company News

Sosei genitourinary, neurology news

Sosei is cutting costs and streamlining operations, including closing its R&D office in Cambridge, U.K. The company said closing the office will reduce its staff by 40 (53%) to 36 and result in annual cost...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Nomura's investments

Nomura's investments Nomura's investments Nomura Phase4 Ventures has invested in at least 25 biotechs since 1999. Usually Nomura's contribution for an initial investment will be some $15-$25 million of the round, although in subsequent rounds...
08:00 , Nov 5, 2007 |  BC Week In Review  |  Company News

Serentis Inc. management update

Serentis Inc. , Cambridge, U.K.   Business: Dermatology, Other   Hired: Peter Keen as corporate development and finance director, former CFO of Arakis Ltd.  ...
07:00 , Jul 2, 2007 |  BioCentury  |  Finance

Calling card put away

When GlaxoSmithKline gained an exclusive option in 2004 to all of Theravance's programs through August 2007, the initial worry among investors was that THRX had become a hostage to the pharma giant. That turned out...
08:00 , Feb 5, 2007 |  BioCentury  |  Strategy

AstraZeneca remodels its house

While it was a latecomer to partnering and M&A as a means of bolstering its pipeline, AstraZeneca plc under the stewardship of CEO David Brennan has sent a strong message to the market that it...
08:00 , Dec 4, 2006 |  BC Week In Review  |  Clinical News

AD 452: Development discontinued

Sosei discontinued development of AD 452 for RA after the compound missed the primary endpoint of ACR20 response at week 12 in a U.S. and European Phase IIb trial. In the double-blind, placebo-controlled trial in...
08:00 , Dec 4, 2006 |  BioCentury  |  Finance

Ebb & Flow

ConjuChem (TSX:CJB) recently disclosed positive Phase I/II data for PC-DAC: Exendin-4 , a once-weekly therapeutic to treat diabetes. But the company was in a bind. It only had C$19 million ($16.7 million) in cash at...